You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 127 No. 1, January 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  STUDIES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Intravenous Administration of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Causes a Cutaneous Eruption

Thomas D. Horn, MD; Philip J. Burke, MD; Judith E. Karp, MD; Antoinette F. Hood, MD

Arch Dermatol. 1991;127(1):49-52.


Abstract

• The intravenous administration of recombinant human granulocyte-macrophage colony-stimulating factor to three patients with leukemia who were receiving marrow aplasiainducing chemotherapy resulted in the development of wide-spread erythematous macules and papules. The course of the eruption paralleled the time of infusion of the granulocyte-macrophage colony-stimulating factor. Skin biopsy specimens taken from two of the eruptions displayed characteristic changes consisting of a variable mixture of granulocytes and lymphocytes, increased number and size of dermal macrophages, mild to moderate epidermal exocytosis, intercellular edema, and rare dyskeratotic keratinocytes. Immunophenotypic analysis of one specimen was notable for keratinocyte intercellular adhesion molecule-1 expression. Administration of the recombinant human cytokine in pharmacologic doses is postulated to induce changes in the immunologic status of the skin, resulting in the expression of a cutaneous eruption.

(Arch Dermatol. 1991;127:49-52)



Author Affiliations

From the Departments of Dermatology (Drs Horn and Hood) and Oncology (Drs Burke and Karp), The Johns Hopkins University School of Medicine, Baltimore, Md.


Footnotes

Accepted for publication August 24, 1990.

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pyoderma Gangrenosum Associated with Acute Megakaryoblastic Leukemia
Crawford
INT J SURG PATHOL 1998;6:177-182.
ABSTRACT  

Recombinant Human Interleukin-3 Induces Extramedullary Hematopoiesis at Subcutaneous Injection Sites in Cynomolgus Monkeys
Khan et al.
Toxicol Pathol 1996;24:391-397.
ABSTRACT  

Leukocyte Colony-Stimulating Factors: A Review of Associated Neutrophilic Dermatoses and Vasculitides
Johnson and Grimwood
Arch Dermatol 1994;130:77-81.
ABSTRACT  

The Sweet Syndrome or G-CSF Reaction?
Karp
ANN INTERN MED 1992;117:875-876.
ABSTRACT  

Cutaneous Reactions to Granulocyte-Monocyte Colony-Stimulating Factor
Mehregan et al.
Arch Dermatol 1992;128:1055-1059.
ABSTRACT  

Interleukin 2 and Granulocyte-Macrophage Colony-Stimulating Factor Induce a Perivascular Lymphocytic Infiltrate in a Skin Explant Model
Horn et al.
Arch Dermatol 1991;127:1789-1793.
ABSTRACT  

Cutaneous Eruptions During GM-CSF Infusion: Clues for Cytokine Biology
Schiro and Kupper
Arch Dermatol 1991;127:110-112.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.